

Synthesis and Characterization of Novel 4-Thiazolidinone Derivatives as Anti-Infective Agents

Monika^{1*} Dr. Piyush Kumar Pathak²

¹ Research Scholar, CTU, Ahmadabad

² Associate Professor, Department of Chemistry, CTU, Ahmadabad

Abstract – A progression of new subsidiaries of 4-thiazolidinone were incorporated, recognized by unearthly procedures, and screened for antimicrobial movement. All the mixes were tried at convergences of 50, 100, 200, 400, 800 and 1600 µg/mL separately against five Gram-positive microscopic organisms, two Gram-negative microbes and two growths. Introductory inhibitory fixations were likewise settled for the two substances and were accounted for to be inside the scope of 100–400 µg/mL. A considerable lot of the mixes showed mellow antimicrobial action to pleasant. The most dynamic mixes of the succession were mixes 4a [2-(4-fluoro-phenyl)- 3-(4-methyl-5,6,7,8-tetrahydro-quinazolin-2-yl)- thiazolidin-4-one] and 4e [3-(4,6-dimethyl-pyrimidin-2-yl)- 2-(2-methoxy-phenyl)-thiazolidin-4-one], demonstrating checked antimicrobial action against *Pseudomonas fluorescens*, *Staphylococcus aureus* and parasitic strains. Hence it might be induced based on the discoveries acquired that combined mixes show a solid scope of antimicrobial activity.

Key Words: Synthesis, Characterization, 4-Thiazolidinone, Derivatives

-----X-----

INTRODUCTION

Microbial maladies are among the main sources of death around the world. A significant concern is the flexibility of a little scope of anti-microbials to battle maladies, and the progressing development of protection from the recently utilized antimicrobials.

Consequently, the advancement of novel and powerful antimicrobials will be the best way to address the issue of opposition and to build up successful medicines for the treatment of irresistible sicknesses. 4-Thiazolidinones have as of late been archived to be novel inhibitors of the bacterial catalyst Mur B (a substrate during peptidoglycan biosynthesis) and even square certain pathogenic bacterial instruments.

4-Thiazolidinones are thiazolidine mixes with a carbonyl gathering in fourth position. This is a focal segment of various engineered drugs that shows a wide scope of natural exercises, for example, antimycobacterial, antimicrobial, anticancer, anticonvulsant, calming and pain relieving, antiparasitic, antiviral and hostile to HIV, antidiabetic, against hypertensive, hostile to hyperlipidemic and MAO inhibitors.

The subbed moiety thiazolidine has attracted considerable consideration the creation of naturally dynamic mixes. In the current examination, 4-thiazolidinones supplanted with novel arylidene is orchestrated and assessed as heterocyclic framework antimicrobial operators.

The synthetics and solvents that were utilized in the examination were gathered from S. D. Great chem. Mumbai Ltd., and Chemie Sigma-Aldrich, Germany. HiMedia Labs, Mumbai, acquired the way of life media for antimicrobial screening.

4-In two phases thiazolidinones is integrated. In the initial step the amalgamation of 1,3-dicarbonyl mixes with guanidine incorporated 2-aminopyrimidine subsidiaries. Last mixes (4a–4f) were blended utilizing DCC as an intermolecular cyclizing specialist by response of Phase 1 mixes with substitution fragrant aldehyde(s) and mercaptoacetic acid(s).

Equimolar arrangement of dicarbonyl and guanidine mixes in ethanol was refluxed for 8 hr at 78 ° C. The response blend under diminished tension was then refined to dryness, and the item was parceled into ethyl acetic acid derivation. The natural covering was splashed with water progressively, and inevitably with saline solution.

The natural covering was dried over sodium sulfate, and the dissolvable was isolated to bring the products (3a–3c) under diminished strain. Tender loving care followed the improvement of the response utilizing 5 percent chloroform methanol.

Table 1

Physical and spectral characterization of the synthesized compounds

Comp.	Melting range	% yield (w/w)	IR (KBr) cm^{-1}	Mass m/z [M + 1] $^{+1}$	$^1\text{H NMR}$ (δ ppm)
4a	Viscous liquid	32.15	1728.1, 3453.60, 1217.2	345	2.37, 3.47, 7.60–6.46
4b	Viscous liquid	59.89	1637.4, 3445.9, 1216.40	374	2.04–2.74, 3.18–3.95, 7.5–6.4
4c	128–130°C	40.11	1711.4, 3418.6, 1216.4 763.7	356	2.73, 3.32, 3.93, 4.35 7.85–6.88
4d	178–180°C	43.04	1691.9, 3296.7, 1592.6	340	1.89, 2.50, 3.07, 4.28 7.87–6.87
4e	114–116°C	59.80	1584.2, 3427.9, 1216.4 1707.4	316	1.25, 3.67, 3.33, 4.29 7.85–6.56
4f	Viscous liquid	37.48	1663.20, 3021.20, 1217.00	306	1.91, 2.56, 3.33, 5.09 6.92–6.80




Figure 1: Synthetic pathway for the compounds

In THF an answer of 3a–3c (10 mmol) and diverse supplanted aldehydes (20 mmol) was mixed for 5 min under super cold conditions, joined by the expansion of mercaptoacetic corrosive (30 mmol). DCC (12 mmol) was applied to the response blend at 0 ° C after 5 min and the response blend was mixed at room temperature for an extra 5 hour. DCU was isolated by filtration, the filtrate gathered at diminished strain to dryness and the remaining was recuperated with ethyl acetic acid derivation. The natural covering was washed progressively with 5% fluid citrus extract, water and 5% watery sodium hydrogen carbonate, and in the long run with saline solution. The natural covering was dried over sodium sulfate, and the dissolvable was isolated to bring the products under diminished strain.

Nine microorganisms, including seven bacterial strains — *Bacillus subtilis* (MTCC 441), *Staphylococcus aureus* (MTCC 1430), *Pseudomonas aeruginosa* (MTCC 424), *Bacillus pumilus* (MTCC 1456), *Pseudomonas fluorescens* (MTCC 2421), *Escherichia coli* (MTCC 1573), and *Micrococcus luteus* (MTCC 1538)— and two parasitic species, *Aspergillus niger*.

The mixes (4a–4f) were broken down at groupings of 50, 100 , 200, 400, 800, and 1600 $\mu\text{g/mL}$ individually in 10 percent DMSO. Norfloxacin and fluconazole, normally utilized as professionally prescribed medications for antibacterial and antifungal tests, were likewise broken down at 10 $\mu\text{g/mL}$ fixations in 10 percent DMSO.

Cup-plate approach was utilized to test antimicrobial action of the integrated mixes. Test microorganism supplement stock suspension (10 mL) was applied to 100 mL of clean liquid agar supplement development media (cooled to 45 ° C), mixed appropriately, and put on sterile petri dishes.

The agar was allowed to cement and afterward punched to make six wells/tasses, utilizing a 6 mm sterile plug drill (separate drill for every life form), to guarantee appropriate dispersion of wells in the fringe and one well in the center. Agar plugs were pulled back and micropipette was utilized to poure 50 μL of test tests (each compound in six focuses) into the particular very much characterized arrangement. Every creature was set up with three-fold plates. The plates were left for 2 h at room temperature to empower test dissemination and afterward face-up brooded for 48 h, at the comparing temperature of every living being.

Diagram Table 2

Mean restraint zone width (mm) of blended mixes (4a–4f), typical and guideline against various miniature living beings.

A progression of glass tubes containing various amounts of integrated mixes (in 10 percent DMSO) with supplement stock is vaccinated with the fundamental inoculum amount to get a suspension of 105 province shaping units for each milliliter of microorganisms. Without appending the mixes or microorganisms one development control tube was fitted. The cylinders have been 24 hour brooded at 37 ° C. An UV noticeable spectrometer estimated the turbidity made in-tube.



S. number	Compounds	Conc. (µg/mL)	Gram +ve strains				Gram -ve strains				Fungal strains	
			SA	BS	BP	ML	PA	PF	EC	AN	PC	
1		50	8	10	8	10	8	14	8	8	9	
		100	9	11	9	10	10	14	10	10	10	
		200	10	11	12	12	13	16	12	11	11	
		400	10	12	16	13	14	17	13	12	13	
		800	11	13	18	14	16	18	13	13	15	
		1600	14	14	20	14	18	19	14	14	17	
(4a-C ₁₈ H ₁₈ FN ₃ OS)												
2		50	8	12	13	15	12	12	8	12	12	
		100	13	13	14	16	13	13	12	14	13	
		200	14	15	15	17	14	15	14	16	14	
		400	15	16	17	18	15	16	15	17	15	
		800	16	17	18	19	17	17	16	18	17	
		1600	18	19	20	21	19	19	18	19	18	

Table 3

Values of the minimum inhibitory concentration of the synthesized compounds and reference standards

S. number	Microbial strains	MIC of compounds (µg/mL)							
		4a	4b	4c	4d	4e	4f	N	F
1	<i>Staphylococcus aureus</i>	300	500	300	400	400	300	2.5	—
2	<i>Bacillus subtilis</i>	300	200	400	300	300	100	5	—
3	<i>Bacillus pumilus</i>	300	100	300	100	200	500	1.25	—
4	<i>Micrococcus luteus</i>	300	500	500	300	300	300	—	—
5	<i>Pseudomonas aeruginosa</i>	200	300	300	300	400	400	2.5	—
6	<i>Pseudomonas fluorescens</i>	100	100	300	100	200	300	2.5	—
7	<i>Escherichia coli</i>	300	100	300	400	400	200	2.5	—
8	<i>Aspergillus niger</i>	300	100	100	100	300	300	—	2.5
9	<i>Penicillium chrysogenum</i>	400	100	100	100	300	300	—	1.25

RESULTS AND DISCUSSION

4-In two phases thiazolidinones is combined. In the initial step the amalgamation of 1,3-dicarbonyl mixes with guanidine incorporated 2-aminopyrimidine subsidiaries. At long last, the mixes (4a–4f) were blended with substitution fragrant aldehydes and mercaptoacetic acids by response of the Phase 1 mixes, using DCC as an intermolecular cyclizer.

Trademark tops for extending of N-H, extending of C = O and extending of C-N were watched. The 4-thiazolidinone subordinates IR spectra indicated C = O lactam amide extending vibration inside 1637–1728 cm⁻¹ territory. [M]⁺/[M+1]⁺ tops for the incorporated mixes were watched. ¹H-NMR spectra of the mixes uncovered the presence of two diastereotopic protons at C-5 and one single proton at C-2; doublets were acquired at 3.07–3.47 ppm level. An upgraded doublet for one proton rose at an estimation of 2.37–2.74 ppm, individually. This can be attributed to the 4-thiazolidinone ring C-2 proton.

Individually, antimicrobial action was identified at 50, 100, 200, 400, 800 and 1600 µg/mL (Table 2). Least convergences of integrated mixes were additionally determined by the cycle of cylinder weakening in

supplement stock. At 530 nm, the MICs were inside the scope of 100–500 µg/mL, announced as the optical power.

The antimicrobial examination indicated that the entirety of the integrated mixes had a huge scope of antimicrobial movement against the microbial strains inspected. At a far higher fixation than the typical medications norfloxacin and fluconazole the mixes, which were dynamic against bacterial and parasitic strains, were fruitful. All the mixes were showing solid to sensible antimicrobial action against all the strains. It was seen that mixes 4b, 4c, and 4d are more specific against parasitic strains than the bacterial strains. In light of the integrated mixes' MIC esteems, the antimicrobial dispersion request was 4b > 4a > 4d > 4c > 4f > 4e. Compound 2-(4-fluoro-phenyl)- 3-(4-methyl-5,6,7,8-tetrahydro-quinazolin-2-yl)-thiazolidin-4-one (4a) and compound 3-(4,6-dimethyl-pyrimidin-2-yl)- 2-(2-methoxy-phenyl)-thiazolidin-4-one (4e) were the most dynamic mixes in the arrangement.

CONCLUSION

In this exploration, six new subordinates of 4-thiazolidinone were integrated, portrayed and assessed for their antimicrobial capacity. The mixes showed antimicrobial action against recognized bacterial Gram-positive and Gram-negative strains and parasitic strains.

The most dynamic individuals from the gathering were distinguished to be 2-(4-fluoro-phenyl)- 3-(4-methyl-5,6,7,8-tetrahydro-quinazolin-2-yl)-thiazolidin-4-one and 3-(4,6-dimethyl-pyrimidin-2-yl)- 2-(2-methoxy-phenyl)-thiazolidin-4-one. In view of the examinations on antimicrobial action it tends to be gathered that all the substances have a full scope of antimicrobial activity.

REFERENCES

- Wright G. D., Daniel T. W. (2003). Chemotherapeutic agents. In: Abraham D. J., editor. *Burger's Medicinal Chemistry and Drug Discovery*. Hoboken, NJ, USA: John Wiley & Sons; 2003. pp. 738.
- Tripathi A. C., Gupta S. J., Fatima G. N., Sonar P. K., Verma A., Saraf S. K. (2014). 4-Thiazolidinones: the advances continue. *European Journal of Medicinal Chemistry*; 72: pp. 52–77.
- Babaoglu K., Page M. A., Jones V. C., et. al. (2013). Novel inhibitors of an emerging target in *Mycobacterium tuberculosis*; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. *Bioorganic and Medicinal Chemistry Letters*; 13(19): pp.

3227–3230. DOI: 10.1016/s0960-894x(03)00673-5.

4. Gouveia F. L., de Oliveira R. M. B., de Oliveira T. B., et. al. (2009). Synthesis, antimicrobial and cytotoxic activities of some 5-arylidene-4-thioxo-thiazolidine-2-ones. *European Journal of Medicinal Chemistry*; 44(5): pp. 2038–2043. DOI: 10.1016/j.ejmech.2008.10.006.
5. Esra T., Küçükgülzel I., Clercq E. D., Sahin F., Güllüce M. (2008). Synthesis, characterization and screening of antimicrobial, antituberculosis, antiviral and anticancer activity of novel 1,3-thiazolidine-4-ones derived from 1-[2-(benzoylamino)-4-(methylthio)butyryl]-4-alkyl/arylalkyl thiosemicarbazides. *ARKIVOC Xiv.*: pp. 191–210.
6. Vicini P., Geronikaki A., Anastasia K., Incerti M., Zani F. (2016). Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene-4-thiazolidinones. *Bioorganic and Medicinal Chemistry*; 14(11): pp. 3859–3864. DOI: 10.1016/j.bmc.2006.01.043.
7. Bondock S., Khalifa W., Fadda A. A. (2007). Synthesis and antimicrobial evaluation of some new thiazole, thiazolidinone and thiazoline derivatives starting from 1-chloro-3,4-dihydronaphthalene 2-carboxaldehyde. *European Journal of Medicinal Chemistry*; 42(7):948–954. DOI: 10.1016/j.ejmech.2006.12.025.
8. Andres C. J., Bronson J. J., D'Andrea S. V., et. al. (2000). 4-Thiazolidinones: novel inhibitors of the bacterial enzyme MurB. *Bioorganic and Medicinal Chemistry Letters*; 10(8): pp. 715–717. DOI: 10.1016/s0960-894x(00)00073-1.
9. Kavitha C. V., Basappa, Swamy S. N., et. al. (2006). Synthesis of new bioactive venlafaxine analogs: novel thiazolidin-4-ones as antimicrobials. *Bioorganic & Medicinal Chemistry*; 14(7): pp. 2290–2299. DOI: 10.1016/j.bmc.2005.11.017.
10. Saeed A., Abbas N., Flörke U. (2007). Synthesis and antibacterial activity of some novel 2-arylimino-3-aryl-thiazolidin-4-ones. *Journal of the Brazilian Chemical Society*; 18(3): pp. 559–565. DOI: 10.1590/s0103-50532007000300010.

Corresponding Author

Monika*

Research Scholar, CTU, Ahmadabad